Perrigo Company plc released its fourth-quarter earnings for the period ending December 31, 2025, via an 8-K filing with the SEC.

BeOne Medicines Ltd. (BGNE) filed an 8-K announcing its financial results for the fourth quarter and full year 2025. The press release, included as Exhibit 99.

Ionis Pharmaceuticals filed an 8-K on February 25, 2026, reporting its financial results for the quarter and fiscal year ended December 31, 2025.

Elanco Animal Health (ELAN) filed an 8-K on February 24, 2026, reporting its financial results for the full year and fiscal quarter ended December 31, 2025.

BioMarin Pharmaceutical Inc. filed an 8-K on February 23, 2026, announcing its financial results for the fourth quarter ended December 31, 2025. The filing includes a press release (Exhibit 99.

Gilead Sciences has announced a definitive agreement to acquire Arcellx, Inc. through a tender offer. Gilead's subsidiary, Ravens Sub, Inc., will offer $115.

Halozyme Therapeutics, Inc. filed an 8-K on February 17, 2026, reporting its financial results for the fourth quarter ended December 31, 2025. The filing includes a press release (Exhibit 99.

Vertex Pharmaceuticals (VRTX) filed an 8-K on February 12, 2026, reporting its consolidated financial results for the three and twelve months ended December 31, 2025.

Moderna, Inc. announced in an 8-K filing that the FDA issued a Refusal-to-File (RTF) letter for its Biologics License Application (BLA) for mRNA-1010, its investigational seasonal influenza vaccine.

Moderna, Inc. filed an 8-K on February 13, 2026, announcing its financial results for the fourth quarter ended December 31, 2025. The announcement was made via a press release furnished as Exhibit 99.